Punctal plug with active agent

• US 9,463,114 B2
• Filed: 08/29/2014
• Issued: 10/11/2016
• Est. Priority Date: 04/15/2004
• Status: Expired due to Term

• Current Assignee: Mati Therapeutics, Inc
• Original Assignee: Mati Therapeutics, Inc
• Inventors: Odrich, Steven A., Glazer, Liane C.
• Primary Examiner(s): WESTERBERG, NISSA M
• Application Number:
  US14/472,844
• Publication Number:
  US 20150132358A1
• Time in Patent Office: 774 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/007 Methods or devices for eye surgery
• CPC Class Codes: A61F 9/00772 Apparatus for restoration of tear ducts
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.

Claims

1. A method for administering an active agent to a subject using a punctal plug, the method comprising:

inserting the punctal plug into a punctal aperture of the subject, wherein the composition of the punctal plug comprises;

a) an active agent selected from the group consisting of topical prostaglandin;

latanoprost;

travoprost;

bimatoprost;

a medication for treatment of a corneal infection;

ciprofloxacin;

moxifloxacin;

gatifloxacin;

a systemic medication;

a medication for treating hypertension;

atenolol;

nifedipine;

hydrochlorothiazide; and

a medication for treating allergic conjunctivitis, and

b) a porous or absorbent material, and

wherein the shape of the punctal plug consists of a constant diameter cylinder configured to be inserted into a canalicular puncta of the subject.

2. The punctal plug of claim 1, wherein the topical prostaglandin is latanoprost.

3. The punctal plug of claim 1, wherein the topical prostaglandin is travoprost.

4. The punctal plug of claim 1, wherein the topical prostaglandin is bimatoprost.

5. The punctal plug of claim 1, wherein the active agent is moxifloxacin.

6. The punctal plug of claim 1, wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.

7. The punctal plug of claim 1, wherein the plug body comprises hydrophilic polymers.

8. A method for administering an active agent to a subject using a punctal plug, the method comprising:

inserting the punctal plug into a punctal aperture of the subject, wherein the composition of the punctal plug comprises;

a) an active agent selected from the group consisting of topical prostaglandin;

latanoprost;

travoprost;

bimatoprost;

a medication for treatment of a corneal infection;

ciprofloxacin;

moxifloxacin;

gatifloxacin;

a systemic medication;

a medication for treating hypertension;

atenolol;

nifedipine;

hydrochlorothiazide; and

a medication for treating allergic conjunctivitis, and

b) a hydrophilic polymer, and

wherein the shape of the punctal plug consists of a constant diameter cylinder configured to be inserted into a canalicular puncta of the subject.

9. The punctal plug of claim 8, wherein the topical prostaglandin is latanoprost.

10. The punctal plug of claim 8, wherein the topical prostaglandin is travoprost.

11. The punctal plug of claim 8, wherein the topical prostaglandin is bimatoprost.

12. The punctal plug of claim 8, wherein the active agent is moxifloxacin.

13. The punctal plug of claim 8, wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.

14. A method for administering an active agent to a subject using a punctal plug, the method comprising:

inserting the punctal plug into a punctal aperture of the subject, wherein the composition of the punctal plug comprises;

a) an active agent wherein the active agent is selected from the group comprising;

travoprost;

moxifloxacin; and

a medication for treating allergic conjunctivitis, and

b) a hydrophilic polymer,

wherein the shape of the punctal plug consists of a constant diameter cylinder configured to be inserted into a canalicular puncta of the subject.